SIETES :: 92794 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]

2.

Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]

3.

Taylor P. Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows. PMLiVE 2019:28 de junio. [Ref.ID 103148]

4.

Xie Y, Bowe B, Yan Y, Xian H, Li T. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:30 de mayo. [Ref.ID 103138]

5.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie MA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92:5 de marzo. [Ref.ID 103132]

6.

Healy D. EMA acknowledges persistent sexual dysfunction after SSRIs & SNRIs. Rxisk 20019:11 de junio. [Ref.ID 103130]

7.

Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]

8.

Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. Ann Intern Med 2019:7 de mayo. [Ref.ID 103117]

9.

Pinto T. Las farmacéuticas se apoyan en EEUU y Alemania para frenar en la OMS un plan que haga más transparente el precio de la medicinas. eldiario.es 2019:15 de mayo. [Ref.ID 103116]

10.

Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]

11.

Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]

12.

McGreal C. Primera condena penal al director de una farmacéutica por su papel en la epidemia de opiáceos que asola EEUU. eldiario.es 2019:3 de mayo. [Ref.ID 103089]

13.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

14.

Jones G. Orphan drugs market to soar to $224bn by 2024. Cell and gene therapies to fuel growth. PMLiVE 2019:25 de abril. [Ref.ID 103080]

15.

Sánchez Caballero D. La ONU mantiene el estatus del cannabis, que sigue al mismo nivel de control que la heroína pese a la recomendación de la OMS. eldiario.es 2019:16 de abril. [Ref.ID 103078]

16.

Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]

17.

Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]

18.

Anónimo. FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. U.S. Food and Drug Administration 2019:22 de marzo. [Ref.ID 103071]

19.

Brownlee S, Garber J. Overprescribed: High cost isn’t America’s only drug problem. STAT Daily Recap 2019:2 de abril. [Ref.ID 103070]

20.

Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019:26 de marzo. [Ref.ID 103069]